

Call for Proposals

EUR 4 million for GMP production of clinical study material for gene and cell therapies

until November 14, 2025

ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (ForTra), is announcing a call for proposals to produce gene and cell therapeutics under Good Manufacturing Practice (GMP) conditions which are intended to be subsequently utilized in a clinical study involving patients.

Gene and cell therapies are developing rapidly and are key to future medical treatment strategies. This is being addressed, among other things, by the funding measures of the [National Strategy for Gene and Cell-Based Therapies](#).

The implementation of clinical studies is a cost-intensive and mandatory step on the path to translating novel gene and cell therapies into clinical application. ForTra is going to enable individual innovative projects that address a high medical need to carry out a clinical study by financially supporting the production of the given study material under GMP conditions as prescribed by law. The entire production process or individual parts thereof shall be funded for a variety of gene and cell therapeutics. Up to four million euros will be provided by ForTra for the whole call.

Eligible to submit proposals for the non-profit funding are clinician and medical scientists employed by academic research facilities (hospital clinics, research institutes, etc.) or other non-profit scientific entities.

The selection procedure for identification of funded projects consists of two steps: Proposal outlines can be submitted via email until November 14, 2025 to antrag@fortra-forschungstransfer.de. Information regarding the details of proposal submission can be found on the [website](#).

An external panel of expert reviewers uses the outlines to identify individual projects whose principal investigators are subsequently requested to submit a full application. Following assessment and recommendation of the full applications by the expert reviewers (including personal pitching of the project) and approval by the internal Board of Translational Research and the Foundation Board, ForTra will send out the positive evaluation and financing decisions presumably in the first quarter of 2026.

ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (ForTra) is recognised as a non-profit organisation under German tax law. The purpose of the company is the support of medical science and research, as well as the promotion of public health, by transferring medical research results into clinical application for the benefit of patients and public healthcare.

Contact ForTra

Prof. Dr. Martin Zörnig

Managing Director ForTra

Rathausplatz 3-7 | 61348 Bad Homburg v. d. Höhe

m.zoernig@fortra-forschungstransfer.de, tel.: +49 (0)6172-8975-12